Memo Therapeutics AG

Corporate information

ETH spin-off Memo Therapeutics has developed a novel technology for rapid discovery of antibodies. Current methods to identify antibodies for drug development are based on investigating individual antibodies at a time and are very cost and time-intensive. Instead of focussing on one antibody at a time, Memo Therapeutics’ solution makes an individual’s entire antibody repertoire searchable and repeatedly accessible for drug discovery. This novel approach is 100-1000 times more efficient in finding rare antibodies for drug development.